WO2008074315A3 - Diagnose und risikostratifizierung mittels dem neuen marker ct-proadm - Google Patents

Diagnose und risikostratifizierung mittels dem neuen marker ct-proadm Download PDF

Info

Publication number
WO2008074315A3
WO2008074315A3 PCT/DE2007/002300 DE2007002300W WO2008074315A3 WO 2008074315 A3 WO2008074315 A3 WO 2008074315A3 DE 2007002300 W DE2007002300 W DE 2007002300W WO 2008074315 A3 WO2008074315 A3 WO 2008074315A3
Authority
WO
WIPO (PCT)
Prior art keywords
proadm
marker
diagnosis
diseases
risk
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/DE2007/002300
Other languages
English (en)
French (fr)
Other versions
WO2008074315A2 (de
Inventor
Andreas Bergmann
Joachim Struck
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BRAHMS GmbH
Original Assignee
BRAHMS GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP07856143A priority Critical patent/EP2111552B1/de
Priority to JP2009541760A priority patent/JP5379018B2/ja
Priority to US12/520,159 priority patent/US8436135B2/en
Priority to ES07856143T priority patent/ES2383711T3/es
Priority to AT07856143T priority patent/ATE552504T1/de
Priority to CN200780047509.XA priority patent/CN101611314B/zh
Application filed by BRAHMS GmbH filed Critical BRAHMS GmbH
Publication of WO2008074315A2 publication Critical patent/WO2008074315A2/de
Publication of WO2008074315A3 publication Critical patent/WO2008074315A3/de
Anticipated expiration legal-status Critical
Priority to US13/782,027 priority patent/US8853355B2/en
Priority to US14/478,639 priority patent/US9726675B2/en
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6884—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from lung
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Die Erfindung betrifft einen neuen diagnostischen Marker CT-proADM (C-terminales Fragment des preproADM, SEQ ID No. 1) zur Diagnose und / oder Risikostratifizierung von Krankheiten. Ferner ein Verfahren zur Diagnose und / oder Risikostratifizierung von Erkrankungen, insbesondere Herz-Kreislauf erkrankungen, Herzinsuffizienz, Infektionen und /oder Entzündungen von Lunge und Atemwege, wobei eine Bestimmung des Markers CT-proADM (SEQ ID No. 1) oder ein Teilpeptid oder Fragment davon oder enthaltend in einer Markerkombination (Panel, Cluster) an einem zu untersuchenden Patienten durchgeführt wird. Weiterhin betrifft die Erfindung eine diagnostische Vorrichtung und ein Kit zur Durchführung des Verfahrens.
PCT/DE2007/002300 2006-12-20 2007-12-20 Diagnose und risikostratifizierung mittels dem neuen marker ct-proadm Ceased WO2008074315A2 (de)

Priority Applications (8)

Application Number Priority Date Filing Date Title
JP2009541760A JP5379018B2 (ja) 2006-12-20 2007-12-20 新規な診断マーカーであるｃｔ−プロａｄｍによる診断および危険性の層化
US12/520,159 US8436135B2 (en) 2006-12-20 2007-12-20 Diagnosis and risk stratification by determining the marker CT-proADM
ES07856143T ES2383711T3 (es) 2006-12-20 2007-12-20 Diagnóstico y estratificación de riesgos mediante el nuevo marcador CT-proADM
AT07856143T ATE552504T1 (de) 2006-12-20 2007-12-20 Diagnose und risikostratifizierung mittels dem neuen marker ct-proadm
CN200780047509.XA CN101611314B (zh) 2006-12-20 2007-12-20 利用新颖标志物CT-proADM进行诊断和危险分层
EP07856143A EP2111552B1 (de) 2006-12-20 2007-12-20 Diagnose und risikostratifizierung mittels dem neuen marker ct-proadm
US13/782,027 US8853355B2 (en) 2006-12-20 2013-03-01 Diagnosis and risk stratification by determining the marker CT-proADM
US14/478,639 US9726675B2 (en) 2006-12-20 2014-09-05 Diagnosis and risk stratification by determining the marker CT-proADM

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102006060112A DE102006060112A1 (de) 2006-12-20 2006-12-20 Diagnose und Risikostratifizierung mittels dem neuen Marker CT-proADM
DE102006060112.2 2006-12-20

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/520,159 A-371-Of-International US8436135B2 (en) 2006-12-20 2007-12-20 Diagnosis and risk stratification by determining the marker CT-proADM
US13/782,027 Continuation US8853355B2 (en) 2006-12-20 2013-03-01 Diagnosis and risk stratification by determining the marker CT-proADM

Publications (2)

Publication Number Publication Date
WO2008074315A2 WO2008074315A2 (de) 2008-06-26
WO2008074315A3 true WO2008074315A3 (de) 2008-09-12

Family

ID=39431425

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE2007/002300 Ceased WO2008074315A2 (de) 2006-12-20 2007-12-20 Diagnose und risikostratifizierung mittels dem neuen marker ct-proadm

Country Status (8)

Country Link
US (3) US8436135B2 (de)
EP (1) EP2111552B1 (de)
JP (1) JP5379018B2 (de)
CN (2) CN101611314B (de)
AT (1) ATE552504T1 (de)
DE (1) DE102006060112A1 (de)
ES (1) ES2383711T3 (de)
WO (1) WO2008074315A2 (de)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103119446A (zh) * 2010-06-18 2013-05-22 B.R.A.H.M.S有限公司 预测癌症发生的生物标志物
CN102428368B (zh) * 2009-05-05 2015-04-22 B.R.A.H.M.S有限公司 患有内皮功能/功能障碍相关疾病的患者的基于血管活性激素的分层

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1628136A1 (de) * 2004-08-19 2006-02-22 B.R.A.H.M.S. Aktiengesellschaft Diagnoseverfahren für Krankheiten unter Verwendung von Copeptin
US8906857B2 (en) * 2005-12-01 2014-12-09 B.R.A.H.M.S. Gmbh Methods for the diagnosis and treatment of critically ill patients with endothelin, endothelin agonists and adrenomedullin antagonists
DE102006060112A1 (de) 2006-12-20 2008-06-26 Brahms Aktiengesellschaft Diagnose und Risikostratifizierung mittels dem neuen Marker CT-proADM
DE102007009751A1 (de) 2007-02-28 2008-09-04 B.R.A.H.M.S Aktiengesellschaft Verfahren zur selektiven Bestimmung von Procalcitonin 1-116 für diagnostische Zwecke sowie Antikörper und Kits zur Durchführung eines solchen Verfahrens
JP5711131B2 (ja) * 2008-10-07 2015-04-30 ベー．エル．アー．ハー．エム．エス ゲゼルシャフト ミット ベシュレンクテル ハフツング 最初の有害事象の予測のためのバイオマーカー
US20100159474A1 (en) * 2008-11-11 2010-06-24 B.R.A.H.M.S. Aktiengesellschaft Prognosis and risk assessment in patients suffering from heart failure by determining the level of adm and bnp
CN102812362B (zh) * 2010-01-08 2015-02-11 卡瓦迪斯有限责任公司 用于预测心血管事件的外来体生物标志物的确定
US9709565B2 (en) 2010-04-21 2017-07-18 Memed Diagnostics Ltd. Signatures and determinants for distinguishing between a bacterial and viral infection and methods of use thereof
WO2012059477A1 (en) * 2010-11-01 2012-05-10 B.R.A.H.M.S Gmbh Prognosis and risk assessment of patients with non-specific complaints
EP3367099B1 (de) 2012-02-09 2021-05-26 Memed Diagnostics Ltd. Signaturen und determinanten zur diagnose von infektionen und verfahren zur verwendung davon
EP2637023A1 (de) * 2012-03-08 2013-09-11 B.R.A.H.M.S GmbH Vorhersage der Ergebnisse bei Patienten mit chronisch obstruktiver Lungenerkrankung
EP2976646B1 (de) * 2013-03-20 2020-08-19 sphingotec GmbH Adrenomedullin zur führung einer therapie von blutdruckabfall
BR112017002884A2 (pt) 2014-08-14 2018-01-30 Memed Diagnostics Ltd ?análise computacional de dados biológicos por meio do uso de variedade e hiperplano?
US20170234873A1 (en) 2014-10-14 2017-08-17 Memed Diagnostics Ltd. Signatures and determinants for diagnosing infections in non-human subjects and methods of use thereof
CN111624345A (zh) 2014-12-11 2020-09-04 米密德诊断学有限公司 用于诊断多种感染的标记组合及其使用方法
CN104655849B (zh) * 2015-02-15 2016-08-24 河北博海生物工程开发有限公司 一种肿瘤靶标的筛选方法
EP3423590A4 (de) 2016-03-03 2020-02-26 Memed Diagnostics Ltd. Rna-determinanten zur unterscheidung zwischen bakteriellen und viralen infektionen
IL287757B (en) 2016-03-03 2022-07-01 Memed Diagnostics Ltd Analyzing rna for diagnosing infection type
EP4231018A3 (de) 2016-07-08 2023-11-15 SphingoTec GmbH Adrenomedullin zur beurteilung der kongestion in einer person mit akutem herzversagen
EP3482200B1 (de) 2016-07-10 2022-05-04 Memed Diagnostics Ltd. Proteinsignaturen zur unterscheidung zwischen bakteriellen und viralen infektionen
EP3482201B1 (de) 2016-07-10 2022-12-14 Memed Diagnostics Ltd. Frühe diagnose von infektionen
EP3279667A1 (de) * 2016-08-02 2018-02-07 Abbott Laboratories Herz-troponin i und copeptin als biomarker für kurzfristige sterblichkeit bei akuter exazerbation von chronisch obstruktiver lungenerkrankung (aecopd)
WO2018060998A1 (en) 2016-09-29 2018-04-05 Memed Diagnostics Ltd. Methods of prognosis and treatment
WO2018060999A1 (en) 2016-09-29 2018-04-05 Memed Diagnostics Ltd. Methods of risk assessment and disease classification
JP6855118B2 (ja) * 2017-03-14 2021-04-07 東ソー株式会社 全身状態の良不良を評価するための情報を提供する方法及び測定試薬
US10209260B2 (en) 2017-07-05 2019-02-19 Memed Diagnostics Ltd. Signatures and determinants for diagnosing infections and methods of use thereof
EP3438668A1 (de) 2017-08-04 2019-02-06 B.R.A.H.M.S GmbH Diagnose und risikostratifizierung von pilzinfektionen
EP3971572A1 (de) 2017-09-13 2022-03-23 B.R.A.H.M.S GmbH Proadrenomedullin als marker für anormale thrombozytenspiegel
WO2019053116A1 (en) 2017-09-13 2019-03-21 B.R.A.H.M.S Gmbh FLUID THERAPY GUIDING METHOD BASED ON PROADRENOMEDULLINE
SG11202002268XA (en) * 2017-10-18 2020-04-29 Adrenomed Ag Therapy monitoring under treatment with an anti-adrenomedullin (adm) binder
EP3502706A1 (de) * 2017-12-20 2019-06-26 B.R.A.H.M.S GmbH Workflow für risikobewertung und patientenmanagement unter verwendung von procalcitonin und midregional-proadrenomedullin
US20210302440A1 (en) 2018-02-08 2021-09-30 Sphingotec Gmbh Adrenomedullin (adm) for diagnosis and/or prediction of dementia and anti-adrenomedullin binder for use in therapy or prevention of dementia
US12181474B2 (en) 2018-06-01 2024-12-31 B.R.A.H.M.S Gmbh Biomarkers for the diagnosis of invasive fungal infections
EP3578989A1 (de) 2018-06-06 2019-12-11 B.R.A.H.M.S GmbH Pro-adm zur prognose von traumabedingten komplikationen bei polytraumapatienten
US12001939B2 (en) 2018-12-11 2024-06-04 Eko.Ai Pte. Ltd. Artificial intelligence (AI)-based guidance for an ultrasound device to improve capture of echo image views
US12400762B2 (en) 2018-12-11 2025-08-26 Eko.Ai Pte. Ltd. Automatic clinical workflow that recognizes and analyzes 2D and doppler modality echocardiogram images for automated cardiac measurements and diagnosis of cardiac amyloidosis and hypertrophic cardiomyopathy
US12322100B2 (en) 2018-12-11 2025-06-03 Eko.Ai Pte. Ltd. Automatic clinical workflow that recognizes and analyzes 2D and doppler modality echocardiogram images for automated cardiac measurements and grading of aortic stenosis severity
US11446009B2 (en) 2018-12-11 2022-09-20 Eko.Ai Pte. Ltd. Clinical workflow to diagnose heart disease based on cardiac biomarker measurements and AI recognition of 2D and doppler modality echocardiogram images
US11931207B2 (en) 2018-12-11 2024-03-19 Eko.Ai Pte. Ltd. Artificial intelligence (AI) recognition of echocardiogram images to enhance a mobile ultrasound device
EP3914913A1 (de) * 2019-02-21 2021-12-01 B.R.A.H.M.S GmbH Verfahren zur diagnose von macce bei patienten nach einer gastrointestinalen chirurgie
EP3928099A1 (de) * 2019-02-21 2021-12-29 B.R.A.H.M.S GmbH Diagnose oder prognose postoperativer nebenwirkungen
WO2020201078A1 (en) 2019-03-29 2020-10-08 B.R.A.H.M.S Gmbh Prescription of remote patient management based on biomarkers
EP3715851A1 (de) 2019-03-29 2020-09-30 B.R.A.H.M.S GmbH Verschreibung von fernpatientenmanagement auf der basis von biomarkern
BR112022002856A2 (pt) 2019-08-30 2022-08-09 4TEEN4 Pharmaceuticals GmbH Orientação de terapia e/ou monitoramento de terapia para o tratamento de choque
EP4023218A1 (de) 2020-12-02 2022-07-06 S-Form Pharma Kombinationstherapie für patienten mit akuter und/oder anhaltender dyspnoe
EP4345109A1 (de) 2022-09-30 2024-04-03 AdrenoMed AG Anti-adrenomedullin (adm)-bindemittel zur verwendung bei der behandlung von pädiatrischen patienten mit angeborener herzerkrankung
WO2026046968A1 (en) 2024-08-26 2026-03-05 4TEEN4 Pharmaceuticals GmbH Dpp3 binders for the treatment of endothelial dysfunction
WO2026046978A1 (en) 2024-08-26 2026-03-05 Pam Theragnostics Gmbh Anti-adm antibodies, anti-adm antibody fragment or anti-adm non-ig scaffold for therapy or prevention of immune effector cell therapy side effects
WO2026046982A1 (en) 2024-08-26 2026-03-05 Pam Theragnostics Gmbh A method for the prediction of a risk or severity of side effects in a cancer patient that is to be treated or has been treated with immune effector cell therapy (iect)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007316009A (ja) * 2006-05-29 2007-12-06 Univ Of Miyazaki アドレノメデュリン前駆体ｃ末端ペプチドの濃度の上昇を指標として循環器疾患又は炎症性疾患を診断する方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2774769B2 (ja) 1993-04-26 1998-07-09 賢治 寒川 アドレノメデュリン
DE19847690A1 (de) 1998-10-15 2000-04-20 Brahms Diagnostica Gmbh Verfahren und Substanzen für die Diagnose und Therapie von Sepsis und sepsisähnlichen systemischen Infektionen
AUPR005600A0 (en) 2000-09-12 2000-10-05 University Of Sydney, The Diagnostic assay
US7713705B2 (en) * 2002-12-24 2010-05-11 Biosite, Inc. Markers for differential diagnosis and methods of use thereof
DE10316583A1 (de) 2003-04-10 2004-10-28 B.R.A.H.M.S Aktiengesellschaft Bestimmung eines midregionalen Proadrenomedullin-Teilpeptids in biologischen Flüssigkeiten zu diagnostischen Zwecken, sowie Immunoassays für die Durchführung einer solchen Bestimmung
GB0401730D0 (en) * 2004-01-27 2004-03-03 Bioxell Spa Diagnosis method
DE102005036094A1 (de) * 2005-08-01 2007-02-08 B.R.A.H.M.S Ag In vitro Verfahren zur Diagnose von neurodegenerativen Erkrankungen
US8906857B2 (en) * 2005-12-01 2014-12-09 B.R.A.H.M.S. Gmbh Methods for the diagnosis and treatment of critically ill patients with endothelin, endothelin agonists and adrenomedullin antagonists
DE102006046996A1 (de) * 2006-10-01 2008-04-03 Brahms Aktiengesellschaft Diagnose von Infektionen oder Entzündungserkrankungen der Atemwege und Lunge assoziiert mit Herzinsuffizienz
US9012151B2 (en) * 2006-11-09 2015-04-21 B.R.A.H.M.S. Gmbh Methods of diagnosis and risk stratification of adverse events in post myocardial infarction patients using pro-adrenomedullin
DE102006060112A1 (de) * 2006-12-20 2008-06-26 Brahms Aktiengesellschaft Diagnose und Risikostratifizierung mittels dem neuen Marker CT-proADM
DE102007021443A1 (de) * 2007-05-08 2008-11-13 Brahms Aktiengesellschaft Diagnose und Risikostratifizierung mittels NT-proET-1
EP2180322A1 (de) * 2008-10-22 2010-04-28 BRAHMS Aktiengesellschaft Prognostische Biomarker zur Progression von primär chronischen Nierenerkrankungen
ES2772930T3 (es) * 2008-10-31 2020-07-08 Brahms Gmbh Prohormona arginina vasopresina como biomarcador predictivo para la diabetes
WO2011000020A1 (en) * 2009-06-12 2011-01-06 Sbc Research Pty Ltd Enhanced method of detection
US20120149131A1 (en) * 2009-08-28 2012-06-14 B.R.A.H.M.S Gmbh Procalcitonin for the prognosis of adverse events

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007316009A (ja) * 2006-05-29 2007-12-06 Univ Of Miyazaki アドレノメデュリン前駆体ｃ末端ペプチドの濃度の上昇を指標として循環器疾患又は炎症性疾患を診断する方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GUMUSEL BULENT ET AL: "Adrenotensin: An adrenomedullin gene product contracts pulmonary blood vessels", PEPTIDES (TARRYTOWN), vol. 17, no. 3, 1996, pages 461 - 465, XP002484481, ISSN: 0196-9781 *
STRUCK J ET AL: "Identification of an Adrenomedullin precursor fragment in plasma of sepsis patients", PEPTIDES, ELSEVIER, AMSTERDAM, vol. 25, no. 8, 1 August 2004 (2004-08-01), pages 1369 - 1372, XP004551479, ISSN: 0196-9781 *
ZHOU LAN ET AL: "Vasoactive effects of adrenotensin and its interactions with adrenomedullin", CHINESE MEDICAL JOURNAL (ENGLISH EDITION), vol. 113, no. 3, March 2000 (2000-03-01), pages 269 - 271, XP002484524, ISSN: 0366-6999 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102428368B (zh) * 2009-05-05 2015-04-22 B.R.A.H.M.S有限公司 患有内皮功能/功能障碍相关疾病的患者的基于血管活性激素的分层
CN103119446A (zh) * 2010-06-18 2013-05-22 B.R.A.H.M.S有限公司 预测癌症发生的生物标志物

Also Published As

Publication number Publication date
US8436135B2 (en) 2013-05-07
CN103884841B (zh) 2018-01-02
JP5379018B2 (ja) 2013-12-25
ES2383711T3 (es) 2012-06-25
US20100035289A1 (en) 2010-02-11
CN101611314A (zh) 2009-12-23
WO2008074315A2 (de) 2008-06-26
US20150011017A1 (en) 2015-01-08
EP2111552A2 (de) 2009-10-28
US9726675B2 (en) 2017-08-08
DE102006060112A1 (de) 2008-06-26
CN103884841A (zh) 2014-06-25
ATE552504T1 (de) 2012-04-15
JP2010513879A (ja) 2010-04-30
US8853355B2 (en) 2014-10-07
US20130266961A1 (en) 2013-10-10
EP2111552B1 (de) 2012-04-04
CN101611314B (zh) 2014-03-05

Similar Documents

Publication Publication Date Title
WO2008074315A3 (de) Diagnose und risikostratifizierung mittels dem neuen marker ct-proadm
WO2008084402A3 (en) Diagnosis and treatment of alzheimer's and other neurodementing diseases
JP2004532817A5 (de)
WO2004103150A3 (en) Apparatus and method for risk stratification of patients with chest pain of suspected cardiac origin
BRPI0811210A2 (pt) Agente de formação de imagem, composição farmacêutica, métodos de preparação de um agente de formação de imagem, de formação de imagem óptica in vivo do corpo de um mamífero e de detecção, avaliação do estágio, diagnóstico, monitoração da progressão da doença ou monitoração do tratamento de câncer colorretal do corpo de um mamífero, e, kit para a preparação da composição farmacêutica.
WO2007001342A3 (en) Exhaled breath condensate collection and assay system and method
WO2010041046A3 (en) Granin proteins as markers of heart disease
CA2740134C (en) Formulations targeting igfbp7 for diagnosis and therapy of cancer
WO2007044867A3 (en) Imaging agents and methods of use thereof
WO2008058517A3 (de) Diagnose und risikostratifizierung von infektionen und chronischen erkrankungen der atemwege und lunge mittels provasopressin, insbesondere copeptin oder neurophysin ii
JP2008522623A5 (de)
EP2857522A3 (de) Verfahren zur Identifizierung, Beurteilung, Prävention und Behandlung von Lungenerkrankungen sowie Kits dafür mit geschlechtsspezifischer Krankheitsidentifizierung, Beurteilung, Prävention und Behandlung
WO2008067806A3 (de) Diagnose und risikostratifizierung von herzinsuffizienz mittels neurophysin
JP2021513077A5 (de)
WO2009131365A3 (ko) 위암 진단 마커로서의 ｃst1, ｄcc1, ifitm1 또는 ｍelk
WO2005098433A3 (en) Diagnostic assays for alzheimer’s disease
EP2293079A3 (de) Verwendung von Enkephalin-Vorläufern und/oder Fragmenten davon in der medizinischen Diagnostik
WO2005046720A3 (en) Diagnosis, prognosis and treatment of pulmonary diseases using foxa2
JP2012530253A5 (de)
Haczku Role and regulation of lung collectins in allergic airway sensitization
WO2007000320A3 (de) Verfahren zur diagnose von rheumatischen erkrankungen
He et al. MiR-543 regulates the development of chronic obstructive pulmonary disease by targeting interleukin-33.
WO2010012828A3 (en) Glutaminyl cyclase as a diagnostic / prognostic indicator for neurodegenerative diseases
TW200503716A (en) Treatment of bacterial diseases of the respiratory organs
ATE523788T1 (de) ASSAY ZUR DIAGNOSE VON ALZHEIMER BASIEREND AUF DER BESTIMMUNG DES VERHÄLTNISSES VON SEKRETASE-Aß-SPALTPRODUKTEN

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780047509.X

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07856143

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2009541760

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1166/MUMNP/2009

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2007856143

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12520159

Country of ref document: US